First Cohort Benefits From Atsena Therapeutics XLRS Gene Therapy
UF startup Atsena Therapeutics has announced positive preliminary data for its gene therapy candidate ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Kate Therapeutics Debuts With $51 Million Series A To Develop Next-Generation Genetic Medicines To Treat Muscle and Heart Diseases
Kate Therapeutics Inc., a next-generation gene therapy company, has emerged from stealth mode after securing a $51 million Series A financing round. The funding was co-led by Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. Additionally, the company has granted Astellas Pharma Inc. an exclusive worldwide license to develop, manufacture, and commercialize KT430 for the treatment of X-linked myotubular myopathy (XLMTM).
IPOs Could Be Headed for a Rocky Road in 2023
Initial public offerings appear likely to remain sluggish for at least several months to start 2023, while special purpose acquisition companies, which provide businesses with alternative paths to public listings, face headwinds of their own. Hear what University of Florida professor Jay Ritter, has to say about a possible IPO drought.
UF Innovate Hosts First Fast Break Ventures Summit
Investors, innovators, and entrepreneurs convened at the University of Florida Stephen C. O’Connell Center for UF Innovate | Ventures' first-annual Fast Break Ventures Summit. Over 100 attendees met on center court for an afternoon filled with discussion on the state of venture capital in Florida and to hear pitches from six startup companies.
The Threat of a Down Round: How Startups Can Adapt To Protect Their Value
The current funding environment might have a lot of founders questioning how to stay sustainable. How do you address this tough situation? Miguel Fernandez, co-founder and CEO at Capchase gives insights on how startups can better deal with the current funding environment.
I am BIO Podcast: Featuring UF Ventures Director Jackson Streeter
Recently, our very own Jackson Streeter was featured on the I Am BIO (Biotechnology Innovation Organization) Podcast. Hear how UF is spending over 1 billion dollars in research and how their work with AAV could help cure all types of genetic disorders.
Hey Founder, Here’s How To Build Your Brand
Building and establishing your personal brand is key to standing out in the current market. Your brand is your track record plus reputation—everything that people currently know you for. Here are four tangible steps to make yourself and your company stand out!
Acquisition of UF Faculty Startup AbFero Provides Iron Chelators for Numerous Diseases
Late last week, Danish biotech Pharmacosmos announced it had acquired AbFero Pharmaceuticals, a University of Florida startup, for $225 million. AbFero is developing compounds called iron chelators created in Dr. Raymond Bergeron’s lab at UF. Chelators remove extra iron from the body.
Too Much Iron? Pharmacosmos Is Betting $225M on a New Potential Solution for That
Pharmacosmos is putting down $225 million to purchase AbFero, a spinout from Raymond Bergeron’s lab at the University of Florida. Its lead candidate, SP-420, recently completed Phase I safety studies as a treatment for transfusional iron overload.
Pharmacosmos Group Acquires AbFero Pharmaceuticals, Inc.
Pharmacosmos Group, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced the acquisition of UF startup AbFero Pharmaceuticals, Inc., a Boston-based, privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload.
